Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Janssen Biotech, Inc. v. Celltrion Healthcare Co., Ltd. et al
Case Number:
1:17-cv-11008
Court:
Nature of Suit:
Judge:
Firms
- Akin Gump
- Barnes & Thornburg
- Burns & Levinson
- Fish & Richardson
- Fox Rothschild
- Haug Partners
- Kirkland & Ellis
- Leydig Voit
- Nutter McClennen
- Patterson Belknap
- Winston & Strawn
Companies
Sectors & Industries:
-
July 31, 2018
Janssen Loses Remicade Patent Case To Pfizer, Celltrion
A recipe related to Janssen Biotech Inc.'s blockbuster immunosuppressant Remicade was too obvious for any competitor to have legally infringed a patent on it, a Massachusetts federal judge ruled Tuesday, allowing Pfizer Inc. to rest easy about the validity of its new-to-market equivalent to treat arthritis and psoriasis among other common conditions.
-
December 05, 2017
Celltrion Wants Janssen To Give Up Docs From Samsung Suit
Celltrion Inc. on Tuesday asked a Massachusetts federal court to order Janssen Biotech Inc. to turn over documents from Janssen's recently dismissed lawsuit against Samsung Bioepis Co. Ltd., arguing that the information is relevant for its defense against Janssen's instant suit over Pfizer Inc.'s biosimilar anti-inflammatory biologic Remicade.
-
December 04, 2017
Janssen Rips Patent Owner's Bid To Appeal Mid-Case
Celltrion Inc. shouldn't be allowed to appeal a Massachusetts federal court's decision not to dismiss Janssen Biotech Inc.'s patent lawsuit over Pfizer Inc.'s biosimilar of anti-inflammatory biologic Remicade, Janssen said Monday, arguing there was nothing extraordinary about the ruling and that an appeal now would only delay the case.
-
October 31, 2017
'Poorly Drafted' Patent Deals Can't End Janssen Suit: Judge
A Massachusetts federal judge on Tuesday refused to toss Janssen Biotech Inc.'s patent suit targeting Pfizer Inc.'s biosimilar of blockbuster biologic Remicade, despite finding that assignments of patent rights to Janssen were ambiguous and "poorly drafted."
-
October 16, 2017
Janssen Defends Role As Sole Patent Owner In Remicade Suit
Johnson & Johnson doesn't need to be named as a party in patent infringement litigation regarding subsidiary Janssen Biotech Inc.'s blockbuster biologic Remicade, as Janssen has full patent ownership rights, the unit told a Massachusetts federal court Monday.
-
July 12, 2017
Pfizer Assails Janssen Suit Over Remicade Biosimilar
Janssen Biotech Inc.'s patent suit over a biosimilar version of its blockbuster biologic Remicade must be tossed because the suit wasn't filed by all of the patent's co-owners, Pfizer Inc. told a Massachusetts federal judge Tuesday.
-
June 01, 2017
Janssen Takes Another 'Patent Dance' Step In Remicade Case
Janssen Biotech Inc. on Wednesday filed a new lawsuit in Massachusetts federal court over Celltrion's biosimilar for the blockbuster Remicade, yet another step in the so-called patent dance in their long-running dispute.